#1 Clinical Trials Search in Europe

Tilmanocept

Tilmanocept, also known by its brand name Lymphoseek, is an innovative radiotracer being studied in various clinical trials for its potential in imaging and diagnostic applications. This article explores the use of Tilmanocept in clinical trials for conditions such as rheumatoid arthritis, cancer, and lymph node mapping. We’ll examine how this agent works, its potential benefits, and the ongoing research to evaluate its effectiveness and safety in different medical scenarios.

Table of Contents

What is Tilmanocept?

Tilmanocept, also known by its brand name Lymphoseek, is a diagnostic drug used in medical imaging[1][2]. It’s not a treatment itself, but rather a tool that helps doctors detect certain conditions in the body. Tilmanocept is typically combined with a radioactive substance called Technetium-99m (Tc-99m) to create what’s known as a radiotracer[1]. This combination allows the drug to be visible on special imaging scans, helping doctors locate specific areas of interest in the body.

How Does Tilmanocept Work?

Tilmanocept works by targeting a specific receptor called CD206, which is found on certain types of cells in the body, particularly a type of immune cell called macrophages[2]. These cells play important roles in various diseases and conditions. When tilmanocept binds to these cells, it allows doctors to see where they are concentrated in the body using special imaging techniques. This can provide valuable information about the presence and extent of certain diseases.

Conditions Being Studied with Tilmanocept

Researchers are investigating the use of tilmanocept in several different conditions:

  • Rheumatoid Arthritis (RA): This is a chronic inflammatory condition affecting joints. Tilmanocept is being studied to see if it can help predict how well patients will respond to certain RA treatments[1][2].
  • Cancer: Tilmanocept is being researched in various types of cancer, including:
    • Breast cancer: To help identify sentinel lymph nodes (the first lymph nodes where cancer is likely to spread)[6].
    • Melanoma (a type of skin cancer): To potentially predict how well patients will respond to immunotherapy[7].
    • Cervical cancer: To help identify sentinel lymph nodes[9].
    • Brain tumors: To map the lymph nodes that drain from brain tumors[8].
  • Kaposi Sarcoma: This is a type of cancer that can occur in people with weakened immune systems, such as those with HIV. Tilmanocept is being studied to see if it can help detect these tumors[5].

How is Tilmanocept Administered?

Tilmanocept can be given in different ways, depending on what the doctors are trying to examine:

  • Intravenous (IV) injection: The drug is injected directly into a vein. This is often used when examining conditions like rheumatoid arthritis or when looking for cancer that may have spread throughout the body[1].
  • Subcutaneous (SC) injection: The drug is injected just under the skin. This method is sometimes used in studies of rheumatoid arthritis[2].
  • Direct injection near the area of interest: For example, in breast cancer studies, the drug might be injected near the tumor or around the nipple area[6]. In brain tumor studies, it might be injected into the brain tissue around the tumor[8].

Imaging Techniques Used with Tilmanocept

After tilmanocept is administered, various imaging techniques are used to visualize where it has accumulated in the body:

  • SPECT (Single Photon Emission Computed Tomography): This is a type of 3D nuclear imaging that can show where the radiotracer has accumulated in the body[2].
  • SPECT/CT: This combines SPECT imaging with CT (Computed Tomography) scans to provide both functional and anatomical information[7].
  • PET/CT (Positron Emission Tomography/Computed Tomography): In some studies, a different form of tilmanocept (labeled with Gallium-68 instead of Technetium-99m) is used with PET/CT imaging[3].
  • Planar imaging: This is a simpler, two-dimensional form of nuclear imaging that can be used to track the movement of tilmanocept over time[5].

Safety and Side Effects

Based on the information provided in the clinical trials, tilmanocept appears to be generally well-tolerated. In studies of intravenous administration for rheumatoid arthritis, no adverse drug reactions were reported[1]. However, as with any medical procedure involving radiation, there are some considerations:

  • The use of radioactive tracers involves exposure to a small amount of radiation. The levels used in these procedures are considered low and the benefits of the diagnostic information usually outweigh the risks[7].
  • There is a theoretical risk of hypersensitivity reactions due to tilmanocept’s similarity to a substance called dextran. Patients are typically asked about any history of allergic reactions to dextran before receiving tilmanocept[7].
  • As with any injectable drug, there can be minor discomfort at the injection site[7].

Ongoing Research and Future Potential

Tilmanocept is still being actively studied for various uses. Some areas of ongoing research include:

  • Predicting treatment response: In rheumatoid arthritis and melanoma, researchers are investigating whether tilmanocept imaging can help predict how well a patient will respond to certain treatments. This could potentially help doctors choose the most effective treatment for each individual patient[10][7].
  • Improving cancer staging: By helping to identify sentinel lymph nodes more accurately, tilmanocept could improve the staging of cancers like breast cancer and cervical cancer. This could lead to more precise treatment planning[6][9].
  • Understanding brain tumor drainage: The study on brain tumors is exploring how these tumors interact with the lymphatic system, which could provide new insights into how brain cancers spread and potentially lead to new treatment approaches[8].
  • Developing normative databases: Some studies are working to establish what “normal” tilmanocept uptake looks like in healthy individuals. This could help doctors better interpret tilmanocept scans in the future[4].

As research continues, tilmanocept may become a valuable tool in personalizing medical care, helping doctors make more informed decisions about diagnosis and treatment for a variety of conditions.

Aspect Details
Primary Uses Imaging inflammation, lymph node mapping, cancer detection
Conditions Studied Rheumatoid arthritis, melanoma, breast cancer, endometrial cancer, Kaposi’s sarcoma, CNS tumors
Administration Routes Intravenous (IV), subcutaneous (SC), direct tissue injection
Imaging Techniques SPECT/CT, PET/CT, planar imaging
Key Advantages Non-invasive, specific binding to CD206 receptors, potential for early treatment response prediction
Safety Profile Generally well-tolerated, ongoing studies to further evaluate safety
Research Focus Efficacy in various conditions, optimal dosing, comparison with standard techniques

FAQ

  • What is Tilmanocept and how does it work? Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose receptor (CD206) on their surface. It is labeled with technetium-99m (Tc-99m) for imaging purposes. This allows it to be detected using various imaging techniques like SPECT/CT, helping to visualize areas of inflammation or specific cell types in the body.
  • In which medical conditions is Tilmanocept being studied? Tilmanocept is being investigated in clinical trials for various conditions, including rheumatoid arthritis, melanoma, breast cancer, endometrial cancer, Kaposi's sarcoma, and central nervous system tumors. It's also being studied for lymph node mapping in different types of cancer.
  • How is Tilmanocept administered in these clinical trials? The administration of Tilmanocept varies depending on the study and condition being investigated. It can be given intravenously (IV), subcutaneously (SC), or through direct injection into specific tissues. The dose and radioactivity levels also vary across trials.
  • What are the potential benefits of using Tilmanocept in medical imaging? Tilmanocept may offer several benefits, including improved detection of inflammation in conditions like rheumatoid arthritis, more accurate lymph node mapping in cancer patients, and potentially predicting treatment response in some cancers. It could provide a non-invasive way to visualize specific cell types and processes in the body.
  • Are there any known side effects or risks associated with Tilmanocept use? Based on the clinical trials data provided, Tilmanocept appears to be well-tolerated. However, as with any medical procedure involving radiation, there are potential risks. Some studies are specifically designed to evaluate the safety profile of Tilmanocept. Patients should discuss potential risks and benefits with their healthcare providers.

Ongoing Clinical Trials on Tilmanocept

  • Study on Sentinel Lymph Node Biopsy for Parotid Gland Cancer Using Gallium (68Ga) Chloride and Tilmanocept in Patients Undergoing Parotidectomy and Neck Dissection

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Detecting Sentinel Lymph Nodes in Early Oral Cancer Using Gallium-68-Tilmanocept and Technetium-99m in Patients with Oral Cancer

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Sentinel Lymph Node Mapping Using Gallium-68 Chloride and Tilmanocept in Patients with High-Risk Endometrial Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Tilmanocept: A radiotracer that binds to CD206 receptors on macrophages, used for imaging inflammation and lymph node mapping when labeled with technetium-99m.
  • Technetium-99m (Tc-99m): A radioactive isotope commonly used in nuclear medicine for diagnostic imaging procedures.
  • SPECT/CT: Single-Photon Emission Computed Tomography combined with Computed Tomography, an imaging technique that provides both functional and anatomical information.
  • Macrophage: A type of white blood cell that engulfs and digests cellular debris, foreign substances, and pathogens.
  • CD206: A receptor found on the surface of certain macrophages, also known as the mannose receptor.
  • Sentinel Lymph Node: The first lymph node or group of nodes draining a cancer site, important in cancer staging and treatment planning.
  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting the small joints of the hands and feet.
  • Tumor-Associated Macrophages (TAMs): Macrophages found in and around tumors, which can influence cancer progression and treatment response.
  • PET/CT: Positron Emission Tomography combined with Computed Tomography, an imaging technique used to observe metabolic processes in the body.
  • bDMARD: Biologic Disease-Modifying Antirheumatic Drug, a type of medication used to treat rheumatoid arthritis and other autoimmune conditions.

References

  1. https://clinicaltrials.gov/study/NCT03241446
  2. https://clinicaltrials.gov/study/NCT02683421
  3. https://clinicaltrials.eu/trial/study-on-sentinel-lymph-node-mapping-using-gallium-68-chloride-and-tilmanocept-in-patients-with-high-risk-endometrial-cancer/
  4. https://clinicaltrials.gov/study/NCT04947137
  5. https://clinicaltrials.gov/study/NCT03157167
  6. https://clinicaltrials.gov/study/NCT04487912
  7. https://clinicaltrials.gov/study/NCT04663126
  8. https://clinicaltrials.gov/study/NCT04096716
  9. https://clinicaltrials.gov/study/NCT02509585
  10. https://clinicaltrials.gov/study/NCT05246280